Welcome to our dedicated page for Rhythm Pharmaceu news (Ticker: RYTM), a resource for investors and traders seeking the latest updates and insights on Rhythm Pharmaceu stock.
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) is a commercial-stage biopharmaceutical company whose news flow centers on rare neuroendocrine diseases and MC4R pathway–targeted therapies. The company’s updates frequently highlight global commercial performance of its lead product IMCIVREE (setmelanotide), regulatory milestones, and clinical data across multiple rare obesity indications.
Investors following RYTM news can expect regular announcements on net product revenues from global sales of IMCIVREE, including the relative contributions from the United States and international markets. Rhythm also issues press releases on reimbursement developments, such as public reimbursement agreements for IMCIVREE in Canadian provinces and under federal programs for patients with Bardet-Biedl syndrome–related obesity.
Clinical and regulatory news is a major focus. Rhythm reports on Phase 3 trials like TRANSCEND in acquired hypothalamic obesity and EMANATE in genetically caused MC4R pathway diseases, as well as exploratory and Phase 2 studies in Prader-Willi syndrome and other rare conditions. Updates often include topline efficacy and safety data, cardiometabolic outcomes, and patient- and caregiver‑reported measures presented at scientific meetings.
Regulatory communications include FDA actions on supplemental New Drug Applications, PDUFA goal dates and extensions, and EMA validation of Type II variations to existing marketing authorizations. Rhythm also provides information on development of investigational MC4R agonists bivamelagon and RM-718 and preclinical small molecules for congenital hyperinsulinism.
For users tracking RYTM, this news feed offers a centralized view of earnings releases, clinical trial readouts, regulatory decisions and access milestones related to IMCIVREE and Rhythm’s broader rare disease pipeline.
Rhythm Pharmaceuticals announced that NICE has recommended IMCIVREE (setmelanotide) for treating obesity and hyperphagia in patients with Bardet-Biedl syndrome (BBS) aged 6 and above. This recommendation aligns with EMA and MHRA approvals. IMCIVREE is expected to be funded by the NHS in England and Wales within three months. Clinical trials showed a reduction in hyperphagia, weight, and BMI among patients. Common adverse events include skin hyperpigmentation, injection site reactions, nausea, and headache. Rhythm plans to submit to the Scottish Medicines Consortium with a decision expected in 2025.
Rhythm Pharmaceuticals, Inc. announced the granting of inducement restricted stock units to seven new employees as part of their 2022 Employment Inducement Plan. These RSUs cover 15,150 shares of common stock and will vest over a four-year period. The company aims to attract and retain top talent through equity awards.
Rhythm Pharmaceuticals reported first quarter 2024 financial results with $26.0 million in net revenue from global sales of IMCIVREE® (setmelanotide). The company is on track to submit an sNDA to the FDA for pediatric patients aged 2-6 in approved indications. Phase 3 trial for hypothalamic obesity remains on track for topline data readout in 1H 2025. Rhythm secured $150 million in convertible preferred stock financing, funding operations into 2026. The company continues to focus on expanding the global opportunity for setmelanotide and advancing the MC4R portfolio with RM-718 and LB54640 programs.
Rhythm Pharmaceuticals presented data from a Phase 3 pediatrics trial at the Pediatric Endocrine Society Annual Meeting, showcasing setmelanotide's achievement of a 3.04 mean reduction in BMI-Z score and an 18.4% mean reduction in BMI in pediatric patients with specific genetic disorders. The company is on track to submit an sNDA seeking label expansion for pediatric patients by the first half of 2024.
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) announced the publication of results from its Phase 2 study of setmelanotide for treating hypothalamic obesity in The Lancet Diabetes & Endocrinology. The therapy resulted in a 15% reduction in BMI at 16 weeks and a 26% reduction at one year. Topline data from the Phase 3 clinical trial is expected in 2Q 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.